GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Pretax Margin %

Conduit Pharmaceuticals (Conduit Pharmaceuticals) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Conduit Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2024 was $-3.55 Mil. Conduit Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Conduit Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Conduit Pharmaceuticals's Pretax Margin % or its related term are showing as below:


CDT's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.32
* Ranked among companies with meaningful Pretax Margin % only.

Conduit Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Conduit Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Pretax Margin % Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Pretax Margin %
- - -

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Conduit Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Conduit Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's Pretax Margin % falls into.



Conduit Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Conduit Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-0.535/0
= %

Conduit Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-3.552/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conduit Pharmaceuticals  (NAS:CDT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Conduit Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Executives
Intelmed Llc other: See Responses 11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay director, officer: Chief Executive Officer 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Andrew Regan director, 10 percent owner LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc. 10 percent owner, other: See Responses 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd. 10 percent owner, other: See Responses WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh director 38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc 10 percent owner 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg director 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc 10 percent owner 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley director 4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv officer: Chief Accounting Officer 2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron director, officer: CEO, President, and Chairman 16433 BRONCO LANE, POWAY CA 92064